Efmedaglutide alfa vs Liraglutide (Victoza)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: GLP-1 receptor · full Type 2 Diabetes pipeline
Efmedaglutide alfa · Shanmeining
Developed by TJ Biopharma Co., Ltd. and partners
NCT06235086 · Phase 3 · completed
This was a randomized, quadruple-masked Phase 3 trial with 632 participants. Its primary endpoint was met according to the sponsor's announcement of 2026-09-30. The result comes from the sponsor's announcement and the sources read give no power calculation, so the grade is moderate.
Reported efficacy
Changes in glycosylated hemoglobin (HbA1c) from baseline at 28 weeks of treatment (Baseline through Week28): Primary endpoint, HbA1c change at week 28: each TG103 dose non-inferior to dulaglutide 1.5 mg (treatment policy analysis); 15 mg lowered HbA1c 1.38% (CSPC, 2026-09-30). (met)
Result source: NCT06235086
Liraglutide (Victoza)
Marketed by Novo Nordisk
NCT00318461 · Phase 3 · completed
This was a large (n=1091), randomized, double-blind, parallel-group trial with both a placebo-controlled comparison (liraglutide + metformin vs metformin + liraglutide placebo) and an active-controlled comparison (glimepiride + metformin). The primary endpoint was change in HbA1c at week 26, a hard, regulator-accepted outcome for type 2 diabetes. The prespecified primary comparisons for liraglutide 1.2 mg and 1.8 mg/day were met: both were significantly superior to metformin alone (p<0.0001) and non-inferior to glimepiride + metformin within the 0.4% margin. The 0.6 mg dose was superior to metformin but did not meet non-inferiority against glimepiride + metformin, which does not negate the positive results for the clinically relevant doses.
Next expected readout: June 2027 · NCT03883412 (registry estimate)
Reported efficacy
Change in Glycosylated A1c (HbA1c) at Week 26 (week 0, week 26); Change in Glycosylated A1c (HbA1c) at Week 104 (week 0, week 104): Change in Glycosylated A1c (HbA1c) at Week 26 (week 0, week 26): Lira 0.6 + Met -0.69 Percentage point of total HbA1c (Standard Error 0.07) | Lira 1.2 + Met -0.97 Percentage point of total HbA1c (Standard Error 0.07) | Lira 1.8 + Met -1 Percentage point of total HbA1c (Standard Error 0.07) vs Met Mono 0.09 Percentage point of total HbA1c (Standard Error 0.09) | Met + Glim -0.98 Percentage point of total HbA1c (Standard Error 0.07) (met)
Result source: NCT00318461
Results for Type 2 Diabetes
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Efmedaglutide alfa | Liraglutide (Victoza) |
|---|---|---|
| HbA1c, change | —Not posted · NCT06258148 | -0.6% vs 0.4%−1.1 vs placeboNCT0154121527 other results
|
| Body weight, change (kg) | —Not posted · NCT06258148 | -2.3 vs 1.0−3.3 vs placeboNCT0154121522 other results
|
| HbA1c below 7% | —Not posted · NCT06258148 | 63.7% vs 36.5%+27.2 vs placeboNCT015412153 other results
|
| Fasting plasma glucose, change | —Not posted · NCT06258148 | -1.6 vs 1.0−2.6 vs placeboNCT0154121521 other results
|
| 3-point MACE (% with event) | —Not posted · NCT06258148 | 13% vs 14.9%−1.9 vs placeboNCT01179048 |
HbA1c, change
- Efmedaglutide alfa
- —Not posted · NCT06258148
- Liraglutide (Victoza)
- -0.6% vs 0.4%−1.1 vs placeboNCT01541215
27 other results
- -0.6% vs -0.5% NCT00318461
- -1% vs -1.0% NCT00318461
- -0.6% vs -0.5% NCT00318461
- -1.0% vs -1.0% NCT00318461
- -0.4% vs -0.5% NCT00318461
- -0.7% vs -1.0% NCT00318461
- -2.4% vs -1.8% NCT02607306
- -1.8% vs -1.8% NCT02607306
- -1.7% vs -1.2% NCT03172494
- -1.2% vs -1.2% NCT03172494
- -1.9% vs -1.1% NCT03175120
- -1.9% vs -0.7% NCT02911948
- -1.5% vs -1.5% NCT02420262
- -1.8% vs -1.1% NCT01952145
- -0.7% vs 0.7% NCT01541215
- -2.4% vs -1.8% NCT02607306
- -1.8% vs -1.8% NCT02607306
- -2.0% vs -1.7% NCT02501161
- 7.9% vs 8.9% NCT01505673
- 6.4% vs 6.4% NCT02765399
- -1.1% vs -0.5% NCT01907854
- -1.8% vs -1.2% NCT01973231
- -1.7% vs -1.0% NCT02008682
- 4.1% vs 3.4% NCT01966978
- -1.4% vs -1.1% NCT02730377
- -1.3% vs -0.7% NCT01917656
- -1.1% vs 0.2% NCT00318422
Body weight, change (kg)
- Efmedaglutide alfa
- —Not posted · NCT06258148
- Liraglutide (Victoza)
- -2.3 vs 1.0−3.3 vs placeboNCT01541215
22 other results
- -2.5 vs -0.9 NCT01541215
- -2.9 vs 0.7 NCT00318461
- -2.8 vs 0.9 NCT00318461
- -3.0 vs 0.7 NCT00318461
- -2.6 vs 0.9 NCT00318461
- -2.1 vs 0.7 NCT00318461
- -1.8 vs 0.9 NCT00318461
- 1.2 vs 3 NCT02501161
- 2.9 vs 4.1 NCT02607306
- -1 vs 4.1 NCT02607306
- 0.2 vs 1.3 NCT03172494
- -2.5 vs 1.3 NCT03172494
- -0.7 vs 0.5 NCT03175120
- 0.5 vs 2.2 NCT02501161
- -0.7 vs 0.7 NCT02911948
- -0.9 vs 2.6 NCT02420262
- -1.4 vs 1.8 NCT01952145
- -3.8 vs -3.5 NCT02730377
- -3.3 vs -1.8 NCT01907854
- -4.2 vs -3.7 NCT01973231
- -5.4 vs -1.5 NCT01917656
- -0.6 vs 3.1 NCT01966978
HbA1c below 7%
- Efmedaglutide alfa
- —Not posted · NCT06258148
- Liraglutide (Victoza)
- 63.7% vs 36.5%+27.2 vs placeboNCT01541215
3 other results
- 51.8% vs 23.2% NCT02964247
- 76.5% vs 52.6% NCT02008682
- 44% vs 20% NCT01966978
Fasting plasma glucose, change
- Efmedaglutide alfa
- —Not posted · NCT06258148
- Liraglutide (Victoza)
- -1.6 vs 1.0−2.6 vs placeboNCT01541215
21 other results
- -1.1 vs 0.8 NCT01541215
- -1.2 vs -0.6 NCT00318461
- -1.7 vs -1.3 NCT00318461
- -1.2 vs -0.6 NCT00318461
- -1.6 vs -1.3 NCT00318461
- -0.8 vs -0.6 NCT00318461
- -1.1 vs -1.3 NCT00318461
- -3.9 vs -3.7 NCT02501161
- -4.1 vs -4.0 NCT02607306
- -2.6 vs -4.0 NCT02607306
- -3.6 vs -3.5 NCT03172494
- -1.9 vs -3.5 NCT03172494
- -3.6 vs -2.8 NCT03175120
- -4.0 vs -3.8 NCT02501161
- -2.8 vs -2.3 NCT02911948
- 6.4 vs 6.4 NCT02765399
- -2.2 vs -1.2 NCT02730377
- -2.9 vs -1.6 NCT01973231
- -2.3 vs -1.2 NCT02008682
- -0.1 vs 0.1 NCT01917656
- -1.8 vs -0.6 NCT01917656
3-point MACE (% with event)
- Efmedaglutide alfa
- —Not posted · NCT06258148
- Liraglutide (Victoza)
- 13% vs 14.9%−1.9 vs placeboNCT01179048
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Efmedaglutide alfa: 0 of 4 rows · Liraglutide (Victoza): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Liraglutide (Victoza) |
|---|---|
| Dropout rate | 21.1%1.8 mg dailya NCT00318461 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 34 more results18.3%1.2 mg daily NCT00318461 · Phase 3 · combination · Type 2 Diabetes · phase 3 14%0.6 mg daily NCT00318461 · Phase 3 · combination · Type 2 Diabetes · phase 3 3% NCT01179048 · Phase 3 15.2%1.8 mg NCT01541215 · Phase 3 —1.8 mg NCT01541215 · Phase 3 —1.8 mg NCT01541215 · Phase 3 0% NCT03260881 · Phase 4 · registry result, not featured evidence 41.2% NCT01919489 · Phase 4 · registry result, not featured evidence · combination 55.2%1.8 mg NCT02730377 · Phase 4 · registry result, not featured evidence 6.3% NCT02765399 · Phase 4 · registry result, not featured evidence 22% NCT01966978 · Phase 4 · registry result, not featured evidence · combination 10.9% NCT02014740 · Phase 4 · registry result, not featured evidence 0% NCT02299388 · Phase 4 · registry result, not featured evidence 8.6% NCT01505673 · Phase 4 · registry result, not featured evidence 7.9% NCT01907854 · Phase 4 · registry result, not featured evidence 5.4% NCT01973231 · Phase 4 · registry result, not featured evidence 14.7% NCT02008682 · Phase 4 · registry result, not featured evidence 15.1% NCT01917656 · Phase 4 · registry result, not featured evidence · combination — NCT02889510 · Phase 3 · registry result, not featured evidence 5.5%Insulin Degludec/Liraglutide NCT03172494 · Phase 3 · registry result, not featured evidence 16.1%Liraglutide NCT03172494 · Phase 3 · registry result, not featured evidence 55.1% NCT01234649 · Phase 3 · registry result, not featured evidence · combination 4% NCT03175120 · Phase 3 · registry result, not featured evidence 4.3% NCT02501161 · Phase 3 · registry result, not featured evidence 1.5% NCT02964247 · Phase 3 · registry result, not featured evidence 7.6%Insulin Degludec/Liraglutide NCT02607306 · Phase 3 · registry result, not featured evidence 3.7%Liraglutide NCT02607306 · Phase 3 · registry result, not featured evidence 0% NCT02911948 · Phase 3 · registry result, not featured evidence 4.8% NCT02773368 · Phase 3 · registry result, not featured evidence 0.8% NCT02420262 · Phase 3 · registry result, not featured evidence 2.9%IDegLira NCT02298192 · Phase 3 · registry result, not featured evidence 9%IDegLira (1WT) NCT02298192 · Phase 3 · registry result, not featured evidence — NCT01937598 · Phase 3 · registry result, not featured evidence 10.1% NCT01952145 · Phase 3 · registry result, not featured evidence |
| Discontinued due to AEs | 12%1.8 mg dailya NCT00318461 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 34 more results9.5%1.2 mg daily NCT00318461 · Phase 3 · combination · Type 2 Diabetes · phase 3 4.5%0.6 mg daily NCT00318461 · Phase 3 · combination · Type 2 Diabetes · phase 3 — NCT01179048 · Phase 3 0%1.8 mg NCT01541215 · Phase 3 —1.8 mg NCT01541215 · Phase 3 —1.8 mg NCT01541215 · Phase 3 — NCT03260881 · Phase 4 · registry result, not featured evidence 7.4% NCT01919489 · Phase 4 · registry result, not featured evidence · combination 7.9%1.8 mg NCT02730377 · Phase 4 · registry result, not featured evidence — NCT02765399 · Phase 4 · registry result, not featured evidence — NCT01966978 · Phase 4 · registry result, not featured evidence · combination — NCT02014740 · Phase 4 · registry result, not featured evidence — NCT02299388 · Phase 4 · registry result, not featured evidence — NCT01505673 · Phase 4 · registry result, not featured evidence — NCT01907854 · Phase 4 · registry result, not featured evidence — NCT01973231 · Phase 4 · registry result, not featured evidence — NCT02008682 · Phase 4 · registry result, not featured evidence 6.4% NCT01917656 · Phase 4 · registry result, not featured evidence · combination — NCT02889510 · Phase 3 · registry result, not featured evidence 1.4%Insulin Degludec/Liraglutide NCT03172494 · Phase 3 · registry result, not featured evidence 8.3%Liraglutide NCT03172494 · Phase 3 · registry result, not featured evidence — NCT01234649 · Phase 3 · registry result, not featured evidence · combination 0.7% NCT03175120 · Phase 3 · registry result, not featured evidence 0.4% NCT02501161 · Phase 3 · registry result, not featured evidence — NCT02964247 · Phase 3 · registry result, not featured evidence 2.9%Insulin Degludec/Liraglutide NCT02607306 · Phase 3 · registry result, not featured evidence 2.2%Liraglutide NCT02607306 · Phase 3 · registry result, not featured evidence — NCT02911948 · Phase 3 · registry result, not featured evidence — NCT02773368 · Phase 3 · registry result, not featured evidence 0.4% NCT02420262 · Phase 3 · registry result, not featured evidence 1%IDegLira NCT02298192 · Phase 3 · registry result, not featured evidence 2.9%IDegLira (1WT) NCT02298192 · Phase 3 · registry result, not featured evidence — NCT01937598 · Phase 3 · registry result, not featured evidence 3.2% NCT01952145 · Phase 3 · registry result, not featured evidence |
| Serious AEs | 6.6%1.8 mg dailya NCT00318461 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 34 more results10.4%1.2 mg daily NCT00318461 · Phase 3 · combination · Type 2 Diabetes · phase 3 14.9%0.6 mg daily NCT00318461 · Phase 3 · combination · Type 2 Diabetes · phase 3 49.7% NCT01179048 · Phase 3 13.6%1.8 mg NCT01541215 · Phase 3 13.5%1.8 mg NCT01541215 · Phase 3 4.2%1.8 mg NCT01541215 · Phase 3 0% NCT03260881 · Phase 4 · registry result, not featured evidence 38.2% NCT01919489 · Phase 4 · registry result, not featured evidence · combination 9.4%1.8 mg NCT02730377 · Phase 4 · registry result, not featured evidence 0% NCT02765399 · Phase 4 · registry result, not featured evidence 11.1% NCT01966978 · Phase 4 · registry result, not featured evidence · combination 0% NCT02014740 · Phase 4 · registry result, not featured evidence 0% NCT02299388 · Phase 4 · registry result, not featured evidence 2.9% NCT01505673 · Phase 4 · registry result, not featured evidence 3% NCT01907854 · Phase 4 · registry result, not featured evidence 5.9% NCT01973231 · Phase 4 · registry result, not featured evidence 1.6% NCT02008682 · Phase 4 · registry result, not featured evidence 1.3% NCT01917656 · Phase 4 · registry result, not featured evidence · combination 0% NCT02889510 · Phase 3 · registry result, not featured evidence 3.9%Insulin Degludec/Liraglutide NCT03172494 · Phase 3 · registry result, not featured evidence 7.8%Liraglutide NCT03172494 · Phase 3 · registry result, not featured evidence 0% NCT01234649 · Phase 3 · registry result, not featured evidence · combination 4.3% NCT03175120 · Phase 3 · registry result, not featured evidence 11.9% NCT02501161 · Phase 3 · registry result, not featured evidence 2.5% NCT02964247 · Phase 3 · registry result, not featured evidence 6.2%Insulin Degludec/Liraglutide NCT02607306 · Phase 3 · registry result, not featured evidence 5.1%Liraglutide NCT02607306 · Phase 3 · registry result, not featured evidence 2.9% NCT02911948 · Phase 3 · registry result, not featured evidence 2.9% NCT02773368 · Phase 3 · registry result, not featured evidence 4.8% NCT02420262 · Phase 3 · registry result, not featured evidence 6.7%IDegLira NCT02298192 · Phase 3 · registry result, not featured evidence 3.3%IDegLira (1WT) NCT02298192 · Phase 3 · registry result, not featured evidence 0% NCT01937598 · Phase 3 · registry result, not featured evidence 1.8% NCT01952145 · Phase 3 · registry result, not featured evidence |
| Most frequent reported AEs | 1.8 mg dailya nausea 21.5% diarrhoea 16.5% nasopharyngitis 14.9% NCT00318461 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 32 more results1.2 mg daily nausea 17.5% nasopharyngitis 15% headache 14.2% NCT00318461 · Phase 3 · combination · Type 2 Diabetes · phase 3 0.6 mg daily nasopharyngitis 17.8% diarrhoea 12.8% nausea 12.4% NCT00318461 · Phase 3 · combination · Type 2 Diabetes · phase 3 1.8 mg nausea 28.8% (placebo 13.2%) vomiting 25.8% (placebo 8.8%) diarrhoea 22.7% (placebo 16.2%) NCT01541215 · Phase 3 1.8 mg nasopharyngitis 3.8% (placebo 27.9%) vomiting 3.8% (placebo 8.8%) abdominal pain 1.9% (placebo 7.4%) NCT01541215 · Phase 3 1.8 mg hyperglycaemia 2.1% (placebo 5.9%) pharyngitis 2.1% (placebo 5.9%) abdominal pain 0% (placebo 7.4%) NCT01541215 · Phase 3 abdominal distention 31.6% nausea 31.6% NCT03260881 · Phase 4 · registry result, not featured evidence nausea 25% (placebo 14.3%) NCT02765399 · Phase 4 · registry result, not featured evidence gi 77.8% headache 25.9% other ae 7.4% NCT01966978 · Phase 4 · registry result, not featured evidence · combination nausea 29.1% NCT02014740 · Phase 4 · registry result, not featured evidence nausea 31.4% (placebo 19.4%) decreased in apetite 17.1% (placebo 11.1%) diarrhea 11.4% (placebo 8.3%) NCT01505673 · Phase 4 · registry result, not featured evidence nausea 21.8% diarrhoea 16.3% decreased appetite 8.9% NCT01907854 · Phase 4 · registry result, not featured evidence nausea 21.8% diarrhoea 12.4% lipase increased 8.4% NCT01973231 · Phase 4 · registry result, not featured evidence nausea 14.8% decreased appetite 10.9% diarrhoea 8.2% NCT02008682 · Phase 4 · registry result, not featured evidence vomiting 5.3% NCT01917656 · Phase 4 · registry result, not featured evidence · combination gastrointestinal disorders 27.1% (placebo 5.7%) general disorders and administration site conditions 2.9% (placebo 0%) nervous system disorders 2.9% (placebo 2.9%) NCT02889510 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 18.4% diabetic retinopathy 7.8% lipase increased 7.5% NCT03172494 · Phase 3 · registry result, not featured evidence decreased appetite 14.4% diarrhoea 14.4% lipase increased 12.2% NCT03172494 · Phase 3 · registry result, not featured evidence nausea 37.2% (placebo 2.7%) diarrhea 17.9% (placebo 17.3%) allergic reaction to liraglutide 1.3% (placebo 0%) NCT01234649 · Phase 3 · registry result, not featured evidence · combination upper respiratory tract infection 12.6% lipase increased 12% diabetic retinopathy 11.6% NCT03175120 · Phase 3 · registry result, not featured evidence headache 11.5% nasopharyngitis 11.3% diarrhoea 7.7% NCT02501161 · Phase 3 · registry result, not featured evidence nausea 26.2% (placebo 6%) decreased appetite 9.4% (placebo 0%) diarrhoea 9.4% (placebo 3%) NCT02964247 · Phase 3 · registry result, not featured evidence viral upper respiratory tract infection 38.5% constipation 9.8% diabetic retinopathy 6.2% NCT02607306 · Phase 3 · registry result, not featured evidence viral upper respiratory tract infection 34.4% constipation 13.9% diarrhoea 8.8% NCT02607306 · Phase 3 · registry result, not featured evidence viral upper respiratory tract infection 20% diabetic retinopathy 16.2% diarrhoea 14.3% NCT02911948 · Phase 3 · registry result, not featured evidence headache 8.6% viral upper respiratory tract infection 7.7% lipase increased 5.7% NCT02773368 · Phase 3 · registry result, not featured evidence nausea 11.1% influenza 7.1% diarrhoea 6.3% NCT02420262 · Phase 3 · registry result, not featured evidence headache 12.5% (placebo 12.5%) asympomatic hyppglycaemia 6.3% (placebo 0%) nausea 6.3% (placebo 0%) NCT01937598 · Phase 3 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for 32 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Liraglutide (Victoza)
show 27 more results
show 22 more results
show 21 more results
show 3 more results
show 1 more result
show 8 more results
show 7 more results
show 3 more results
+ 129 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Efmedaglutide alfa's landscape · Liraglutide (Victoza)'s landscape